Condition
Neuroendocrine Tumor G2
Total Trials
3
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
3 of 0 completed with results
Key Signals
3 with results
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Active Not Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT03375320Phase 3Active Not Recruiting
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT00569127Phase 3Active Not Recruiting
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
NCT01841736Phase 2Active Not Recruiting
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Showing all 3 trials